Monday, February 27, 2023
Lantern Pharma announced that it has entered into a research and development collaboration with TTC Oncology. The collaboration will focus on leveraging RADR® AI insights to advance TTC Oncology’s first- and best-in-class drug candidate TTC-352 for recurrent ER+ breast cancer patients and additional patient populations potentially identified by RADR®.
The collaboration will utilise Lantern’s AI-based capabilities and RADR® platform to uncover efficacy-associated biological signatures and biomarkers to advance the clinical development and strategic positioning of TTC Oncology’s leading drug candidate, TTC-352. This AI-powered collaboration with TTC Oncology will accelerate the clinical development of TTC-352 for patients with metastatic ER+ breast cancer and will also identify new potential patient populations who can benefit from TTC-352 treatment.
The collaboration is based on RADR's 25 billion oncology-focused data points, 200 advanced ML algorithms, and four versatile AI drug discovery and development modules. The initial aims of the collaboration will be to identify biomarker or gene signatures to power potential patient selection for an upcoming TTC-352 Phase 2 clinical trial, further characterise TTC-352’s mechanism of action, and discover additional treatment indications for TTC-352.
Under the terms of the collaboration, Lantern Pharma will receive the exclusive right to licence TTC-352 during the exclusive option period, including all intellectual property (IP) rights related to the collaboration.
